Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis

Evidence

Liver Int. 2023 Jun 20. doi: 10.1111/liv.15591. Online ahead of print.

ABSTRACT

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and the newly proposed metabolic-associated fatty liver disease (MAFLD) were each associated with subclinical atherosclerosis. However, there is limited evidence on risk of atherosclerosis in individuals who meet the criteria for one but not the other. We aimed to investigate the associations of MAFLD or NAFLD status with site-specific and multiple-site atherosclerosis.

METHODS: This is a prospective cohort study involving 4524 adults within the MJ health check-up cohort. Logistic regression model was used to estimate odds ratios (ORs) and confidence intervals (CIs) for subclinical atherosclerosis (elevated carotid intima-media thickness [CIMT], carotid plaque [CP], coronary artery calcification [CAC] and retinal atherosclerosis [RA]) associated with MAFLD or NAFLD status, MAFLD subtypes and fibrosis status.

RESULTS: MAFLD was associated with higher risks of elevated CIMT, CP, CAC and RA (OR: 1.41 [95% CI 1.18-1.68], 1.23 [1.02-1.48], 1.60 [1.24-2.08], and 1.79 [1.28-2.52], respectively), whereas NAFLD per se did not increase risk of atherosclerosis except for elevated CIMT. Individuals who met both definitions or the definition for MAFLD but not NAFLD had higher risk of subclinical atherosclerosis. Among MAFLD subtypes, MAFLD with diabetes had the highest risk of subclinical atherosclerosis, but the associations did not differ by fibrosis status. Stronger positive associations were observed of MAFLD with multiple-site than single-site atherosclerosis.

CONCLUSIONS: In Chinese adults, MAFLD was associated with subclinical atherosclerosis, with stronger associations for multiple-site atherosclerosis. More attention should be paid to MAFLD with diabetes, and MAFLD might be a better predictor for atherosclerotic disease than NAFLD.

PMID:37337780 | DOI:10.1111/liv.15591

Document this CPD Copy URL Button

Google

Google Keep Add to Google Keep

LinkedIn Share Share on Linkedin Share on Linkedin

Estimated reading time: 5 minute(s)

Latest: Psychiatryai.com #RAISR4D

Real-Time Evidence Search [Psychiatry]

AI Research [Andisearch.com]

Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis

Copy WordPress Title

🌐 90 Days

Evidence Blueprint

Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

More Evidence

Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis

🌐 365 Days

Floating Tab
close chatgpt icon
ChatGPT

Enter your request.